BrightFocus Foundation

Last updated
BrightFocus Foundation
FoundedMay 15, 1973;50 years ago (1973-05-15) [1]
FoundersJanette Michaels, Eugene Michaels
Type Foundation
Focus Alzheimer's disease, macular degeneration, glaucoma, medical research
Location
Coordinates 39°13′38″N77°16′43″W / 39.227134°N 77.278680°W / 39.227134; -77.278680
Stacy Pagos Haller
Subsidiaries National Development LLC, American Health Assistance LLC [2]
Employees (2019)
58 [2]
Volunteers (2019)
51 [2]
Website www.brightfocus.org
Formerly called
The American Health Assistance Foundation

BrightFocus Foundation is a nonprofit organization based in Clarksburg, Maryland. BrightFocus funds research in an effort to discover cures for Alzheimer's disease, macular degeneration and glaucoma, and provides information and free English and Spanish resources to increase awareness about these diseases. Through its research programs — Alzheimer’s Disease Research, National Glaucoma Research, and Macular Degeneration Research — the Foundation has awarded nearly $290 million in research funding. BrightFocus provides free public education and free printed brochures and publications [3] on brain and eye diseases in English and Spanish, including Alzheimer's disease, macular degeneration, and glaucoma. BrightFocus has active research grants in 17 countries and at 154 institutions. [4] BrightFocus Foundation offers free monthly low-vision audio podcast programs with medical experts on Glaucoma and Macular Degeneration and a free expert Alzheimer's video series called "Zoom in On Alzheimer's and Dementia" with medical doctors. [5]

Contents

History

BrightFocus was founded on May 15, 1973, [1] as The American Health Assistance Foundation (AHAF) by husband and wife team, Janette Michaels and Eugene Michaels as Executive Director and President, respectively, and funded research that led to the development of the first artificial heart. [6]

In 2012, BrightFocus Foundation partnered with three other nonprofit organizations as the 21st Century Brain Trust, which was the runner-up in the Collaborate Activate Innovation Challenge, a competition sponsored by Sanofi US, for the Trust's work in developing mobile applications that detect early symptoms of Alzheimer's disease. Effective 1 February 2013 AHAF changed its name to BrightFocus Foundation. The charity selected the new name to better communicate its goals, "to save mind and sight," according to BrightFocus President and CEO Stacy Pagos Haller. [7]

BrightFocus Foundation funded two researchers who went on to win Nobel prizes, [8] Dr. Paul Greengard and Dr. Stanley Prusiner. BrightFocus funded Dr. Joel Schuman, who found the first biomarker for glaucoma and improved OCT. [9]

BrightFocus Foundation provided early funding that led to the first-ever Alzheimer's disease blood test development. [10]

Research programs

BrightFocus Foundation awards grants, fellowships, and produces educational materials and programs through its three research programs, [11] currently funding 287 research projects worldwide:

Awards and recognition

In 2013, BrightFocus Foundation earned a Seal of Excellence from the Maryland Association of Nonprofit Organizations, which requires organizations to go through a rigorous application process to certify that they are well-run and worthy of public trust. [15] [16]

Charity assessment

BrightFocus Foundation has a 4-star rating on Charity Navigator, with an overall score of 96/100 for financial, accountability, impact, community, and leadership. [17] BrightFocus Foundation received a 2022 GuideStar Platinum Transparency certification. [18]

Related Research Articles

The National Eye Institute (NEI) is part of the U.S. National Institutes of Health (NIH), an agency of the U.S. Department of Health and Human Services. The mission of NEI is “to eliminate vision loss and improve quality of life through vision research.” NEI consists of two major branches for research: an extramural branch that funds studies outside NIH and an intramural branch that funds research on the NIH campus in Bethesda, Maryland. Most of the NEI budget funds extramural research.

<span class="mw-page-title-main">British Heart Foundation</span> United Kingdom charity

The British Heart Foundation (BHF) is a cardiovascular research charity in the United Kingdom. It funds medical research related to heart and circulatory diseases and their risk factors, and runs influencing work aimed at shaping public policy and raising awareness.

<span class="mw-page-title-main">Alzheimer's Society</span> United Kingdom care and research charity

Alzheimer's Society is a United Kingdom care and research charity for people with dementia and their carers. It operates in England, Wales and Northern Ireland, while its sister charities Alzheimer Scotland and Alzheimer Society of Ireland cover Scotland and the Republic of Ireland respectively.

<span class="mw-page-title-main">Amsler grid</span> Tool to detect defects in central vision

The Amsler grid, used since 1945, is a grid of horizontal and vertical lines used to monitor a person's central visual field. The grid was developed by Marc Amsler, a Swiss ophthalmologist. It is a diagnostic tool that aids in the detection of visual disturbances caused by changes in the retina, particularly the macula, as well as the optic nerve and the visual pathway to the brain. Amsler grid usually help detecting defects in central 20 degrees of the visual field.

<span class="mw-page-title-main">Jackson Laboratory</span> Biomedical research institution

The Jackson Laboratory is an independent, non-profit biomedical research institution which was founded by Clarence Cook Little in 1929. It employs more than 3,000 employees in Bar Harbor, Maine; Sacramento, California; Farmington, Connecticut; Shanghai, China; and Yokohama, Japan. The institution is a National Cancer Institute-designated Cancer Center and has NIH Centers of Excellence in aging and systems genetics. The mission of The Jackson Laboratory is "to discover the genetic basis for preventing, treating and curing human diseases, and to enable research and education for the global biomedical community."

The National Multiple Sclerosis Society (NMSS) is a nonprofit organization founded in 1946.

<span class="mw-page-title-main">Alzheimer's Association</span> Non-profit American health organization

The Alzheimer's Association was founded by Jerome H. Stone with the help of several family members in Chicago, Illinois. Incorporated on April 10, 1980, as the Alzheimer's Disease and Related Disorders Association, Inc., it is a non-profit American volunteer health organization which focuses on care, support and research for Alzheimer's disease.

The Alliance for Aging Research is a non-profit organization based in Washington, D.C., that promotes medical research to improve the human experience of aging. Founded in 1986 by Daniel Perry, the Alliance also advocates and implements health education for consumers and health professionals.

<span class="mw-page-title-main">Foundation Fighting Blindness</span>

The mission of the Foundation Fighting Blindness is to fund research that will lead to the prevention, treatment and cures for the entire spectrum of retinal degenerative diseases, including retinitis pigmentosa, macular degeneration, Usher syndrome, Stargardt disease and related conditions. These diseases, which affect more than 10 million Americans and millions more throughout the world, often lead to severe vision loss or complete blindness.

John Quinn Trojanowski was an American academic research neuroscientist specializing in neurodegeneration. He and his partner, Virginia Man-Yee Lee, MBA, Ph.D., are noted for identifying the roles of three proteins in neurodegenerative diseases: tau in Alzheimer's disease, alpha-synuclein in Parkinson's disease, and TDP-43 in Amyotrophic Lateral Sclerosis (ALS) and frontotemporal degeneration.

Fight for Sight is a UK charity funding research into the prevention and treatment of blindness and eye disease.

<span class="mw-page-title-main">Vision disorder</span> Medical condition

A vision disorder is an impairment of the sense of vision.

<span class="mw-page-title-main">Alzheimer Society of Canada</span> Canadian health charity

The Alzheimer Society of Canada (ASC) is a Canadian health charity for people living with Alzheimer's disease and other dementias. Active in communities right across Canada, the Society partners with Alzheimer Societies in every Canadian province to offer information, support and education programs for people with dementia, their families and caregivers. The Alzheimer Society of Canada acts as the national voice for the thousands of Canadians living with dementia and advocates on their behalf for positive change. The Society also funds young and established Canadian researchers working to find the causes and a cure through the Alzheimer Society Research Program.

Research to Prevent Blindness (RPB) is a nonprofit organization created in 1960 by Jules Stein, the founder of Music Corporation of America, to stimulate research to eliminate blinding diseases. It supports eye research directed at the prevention, treatment or eradication of all diseases that threaten vision.

<span class="mw-page-title-main">Alzheimer's Foundation of America</span> Non-profit organisation in the USA

The Alzheimer's Foundation of America (AFA) is an American nonprofit organization based in New York City whose mission is to provide support, services and education to individuals, families and caregivers affected by Alzheimer's disease and related dementias nationwide, and fund research for better treatment and a cure. AFA unites more than 2,000 member organizations from coast-to-coast that are dedicated to meeting the educational, social, emotional and practical needs of individuals with Alzheimer's disease and related illnesses, and their caregivers and families. Member organizations include grassroots Alzheimer's agencies, senior centers, adult daycare center, home healthcare agencies, long-term care residences, research facilities, and other dementia-related groups. AFA holds Charity Navigator's highest rating of 4 stars.

<span class="mw-page-title-main">Joel S. Schuman</span>

Joel S. Schuman, MD, FACS is Professor of Ophthalmology, the Kenneth L. Roper Endowed Chair, Vice Chair for Research Innovation and Co-Director of the Glaucoma Service at Wills Eye Hospital. Prior to this he was the Elaine Langone Professor and Vice Chair for Research in the Department of Ophthalmology at NYU Langone Medical Center, NYU Grossman School of Medicine; Professor of Biomedical Engineering and Electrical & Computer Engineering at NYU Tandon School of Engineering and Professor of Neural Science in the Center for Neural Science at NYU College of Arts and Sciences. He chaired the ophthalmology department at NYU Langone Health, NYU Grossman School of Medicine 2016-2020, and was Vice Chair for Ophthalmology Research in the department 2020-2022. Prior to arriving at NYU in 2016, he was Distinguished Professor and Chairman of Ophthalmology, Eye and Ear Foundation Endowed Chair in Ophthalmology, Director of UPMC Eye Center (2003-2016) and before that was at Tufts University 1991-2003, where he was Residency Director (1991-1999) and Glaucoma and Cataract Service Chief (1991-2003). In 1998 he became Professor of Ophthalmology, and Vice Chair in 2001.

<span class="mw-page-title-main">Lineage Cell Therapeutics</span> Clinical-stage biotechnology company developing novel cell therapies

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.

The Alzheimer's Drug Discovery Foundation (ADDF) is a nonprofit organization founded in 1998 by co-chairmen Leonard A. Lauder and Ronald S. Lauder of the Estée Lauder Companies cosmetics family and led by Howard Fillit, a geriatrician and neuroscientist. The ADDF provides funding to scientists who are conducting promising, innovative Alzheimer's disease drug research worldwide. The ADDF funds early-stage research and early-phase clinical trials that might otherwise go unfunded. By supporting research projects around the world, it seeks to increase the chances of finding treatments for Alzheimer's disease, related dementias and cognitive aging. The ADDF has invested nearly $65 million to fund some 450 Alzheimer's drug discovery programs and clinical trials in academic centers and biotechnology companies in 18 countries.

<span class="mw-page-title-main">Cure Alzheimer's Fund</span>

Cure Alzheimer's Fund (CAF) is an American non-profit organization based in Wellesley, Massachusetts. It supports and funds research focusing on understanding and potentially curing Alzheimer's disease utilizing a venture philanthropy approach, targeting research with the highest probability of preventing, slowing or reversing Alzheimer's disease. The board of directors covers all operating costs so that all donations go entirely to research.

The Vision Institute is a research center in the Quinze-Vingts National Eye Hospital in Paris, France. It is one of several such centers in Europe on eye diseases.

References

  1. 1 2 "BrightFocus Foundation", Government of the District of Columbia. Retrieved August 30, 2020.
  2. 1 2 3 "Form 990: Return of Organization Exempt from Tax". BrightFocus Foundation. Internal Revenue Service. December 31, 2019.
  3. ↑ "Request Resources | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  4. ↑ "2022 BrightFocus Research Grant Awards | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  5. ↑ "Latest BrightFocus Chats® | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  6. ↑ "Early Artificial Heart Research Funded by American Health Assistance Foundation | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  7. ↑ Vision Monday. American Health Assistance Foundation Announces Name Change and Survey Results. Published 6 February 2013, Accessed 1 September 2019.
  8. ↑ "Notable Researchers | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  9. ↑ "The High-Impact Career of Joel Schuman, MD | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  10. ↑ ""Next-Generation" Alzheimer's Blood Test Announced, Rooted in Early BrightFocus Funding | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  11. ↑ "Research We Fund | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  12. ↑ "Alzheimer's Insights & Research Breakthroughs | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  13. ↑ "Macular Degeneration Research | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  14. ↑ "National Glaucoma Research | BrightFocus Foundation". www.brightfocus.org. Retrieved 2022-12-20.
  15. ↑ "Maryland Seal Holders". Maryland Association of Nonprofit Organizations. Archived from the original on 13 May 2013. Retrieved 3 June 2013.
  16. ↑ Shatzkin, Kate (29 October 1999). "Maryland group certifies seven charities as worthy; First in nation to apply tougher criteria to boost public confidence". The Baltimore Sun. Retrieved 3 June 2013.
  17. ↑ "Charity Navigator - Rating for BrightFocus Foundation".
  18. ↑ "BrightFocus Foundation - GuideStar Profile". www.guidestar.org. Retrieved 2022-12-20.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.